Polycystic Ovarian Syndrome - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 45 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Polycystic Ovarian Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Polycystic Ovarian Syndrome - Pipeline Review, H2 2014', provides an overview of the Polycystic Ovarian Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycystic Ovarian Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Polycystic Ovarian Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Polycystic Ovarian Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Polycystic Ovarian Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Polycystic Ovarian Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Polycystic Ovarian Syndrome - Overview 7
Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis 8
Polycystic Ovarian Syndrome - Therapeutics under Development by Companies 9
Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes 10
Polycystic Ovarian Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Polycystic Ovarian Syndrome - Products under Development by Companies 14
Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes 15
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development 16
AstraZeneca PLC 16
Euroscreen S.A. 17
Neurocrine Biosciences, Inc. 18
Merck KGaA 19
EffRx Pharmaceuticals S.A. 20
Crinetics Pharmaceuticals, Inc. 21
Polycystic Ovarian Syndrome - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
choriogonadotropin alfa - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AZD-4901 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ESN-364 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
metformin hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Synthetic Peptide to Target GPR54 for Womens Health, Male Health and Oncology - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Synthetic Peptide for Metabolic Syndrome and Polycystic Ovarian Syndrome - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit KISS-1R For Polycystic Ovarian Syndrome - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Polycystic Ovarian Syndrome - Recent Pipeline Updates 40
Polycystic Ovarian Syndrome - Dormant Projects 41
Polycystic Ovarian Syndrome - Product Development Milestones 42
Featured News & Press Releases 42
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 42
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products under Development for Polycystic Ovarian Syndrome, H2 2014 7
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Polycystic Ovarian Syndrome - Pipeline by AstraZeneca PLC, H2 2014 16
Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H2 2014 17
Polycystic Ovarian Syndrome - Pipeline by Neurocrine Biosciences, Inc., H2 2014 18
Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H2 2014 19
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H2 2014 20
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Polycystic Ovarian Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 40
Polycystic Ovarian Syndrome - Dormant Projects, H2 2014 41